TY - JOUR
T1 - Detection of serum/salivary exosomal Alix in patients with oral squamous cell carcinoma
AU - Nakamichi, Eiji
AU - Sakakura, Hiroki
AU - Mii, Shinji
AU - Yamamoto, Noriyuki
AU - Hibi, Hideharu
AU - Asai, Masato
AU - Takahashi, Masahide
N1 - Funding Information:
This work was supported by Grants‐in‐Aid for Scientific Research (B) (JP17H04065 to M.A.) and (S) (26221304 to M.T.) and a Grant‐in Aid for Young Scientists (JP18K17025 to H.S.) from the Japan Society for the Promotion of Science. Particle size analyses were supported by the program of Nanotechnology Platform of the Ministry of Education, Culture, Sports, Science and Technology. M.T. and M.A. designed the study; E.N. performed all experiments and the statistical analysis; M.A., E.N., H.S., and M.T. wrote the manuscript; all authors have proofread the article.
Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2021/4
Y1 - 2021/4
N2 - Objective: Owing to variations in the exterior appearances of noncancerous diseases in the oral cavity, clinicians may have difficulty diagnosing oral squamous cell carcinoma (OSCC). Tissue biopsy is confirmatory, but invasive. Therefore, reliable tumor markers for OSCC are required. Here, exosomal Alix (exoAlix) levels were measured in serum/salivary samples from patients with OSCC and healthy controls (HCs). Methods: Fifty-seven patients admitted to Nagoya University Hospital from 2017 through 2019 were enrolled, and serum samples (OSCC, n = 29; HC, n = 21) and/or saliva samples (OSCC, n = 23; HC, n = 20) were collected. Exosomal fractions were isolated using ultracentrifugation. ExoAlix levels were measured using enzyme-linked immunosorbent assay. Results: Serum/salivary exoAlix levels were significantly higher in patients with OSCC than in HCs. Receiver operating characteristic analyses revealed that sensitivity, specificity, positive predictive value, and area under the curve were 0.345, 1.000, 1.000, and 0.685, respectively, for serum exoAlix and 0.348, 1.000, 1.000, and 0.712, respectively, for salivary exoAlix at optimal cut-off values (serum, 0.205; saliva, 0.193). All tested OSCC tissue sections (n = 21) were immuno-reactive for Alix. Conclusion: Serum and salivary exoAlix were identified as potential diagnostic OSCC biomarkers. Serum exoAlix was suitable for prediction of therapeutic responses.
AB - Objective: Owing to variations in the exterior appearances of noncancerous diseases in the oral cavity, clinicians may have difficulty diagnosing oral squamous cell carcinoma (OSCC). Tissue biopsy is confirmatory, but invasive. Therefore, reliable tumor markers for OSCC are required. Here, exosomal Alix (exoAlix) levels were measured in serum/salivary samples from patients with OSCC and healthy controls (HCs). Methods: Fifty-seven patients admitted to Nagoya University Hospital from 2017 through 2019 were enrolled, and serum samples (OSCC, n = 29; HC, n = 21) and/or saliva samples (OSCC, n = 23; HC, n = 20) were collected. Exosomal fractions were isolated using ultracentrifugation. ExoAlix levels were measured using enzyme-linked immunosorbent assay. Results: Serum/salivary exoAlix levels were significantly higher in patients with OSCC than in HCs. Receiver operating characteristic analyses revealed that sensitivity, specificity, positive predictive value, and area under the curve were 0.345, 1.000, 1.000, and 0.685, respectively, for serum exoAlix and 0.348, 1.000, 1.000, and 0.712, respectively, for salivary exoAlix at optimal cut-off values (serum, 0.205; saliva, 0.193). All tested OSCC tissue sections (n = 21) were immuno-reactive for Alix. Conclusion: Serum and salivary exoAlix were identified as potential diagnostic OSCC biomarkers. Serum exoAlix was suitable for prediction of therapeutic responses.
UR - http://www.scopus.com/inward/record.url?scp=85089091637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089091637&partnerID=8YFLogxK
U2 - 10.1111/odi.13565
DO - 10.1111/odi.13565
M3 - Article
C2 - 32688445
AN - SCOPUS:85089091637
VL - 27
SP - 439
EP - 447
JO - Oral Diseases
JF - Oral Diseases
SN - 1354-523X
IS - 3
ER -